Efficacy and Hypoglycemia Profile of Once-weekly Insulin Icodec vs Once-daily Comparators Across Demographic Subgroups.

Similarly, in ONWARDS 4, the odds of achieving the composite assessment were consistent with those from the overall trial population (no difference observed between treatment arms), with the exception of the <55 years subgroup, which presented a trend favoring the OD comparator, and the 55 to 64 years and Hispanic/Latino subgroups, both of which showed a trend favoring icodec.

also in 53,322 other papers